BRISTOL MYERS SQUIBB COBMY
BRISTOL MYERS SQUIBB CO Financial Overview 2021–2025
Bristol Myers Squibb engineered a dramatic financial turnaround, swinging from a $-4.41 per share loss in FY2024 to profitable earnings of $3.46 per share in FY2025. This volatility underscores a deliberate strategy to absorb heavy upfront costs—driven by patent cliffs for established drugs like Revlimid—in exchange for pipeline longevity. The company’s core investment thesis relies on aggressively leveraging its balance sheet to replace expiring revenue streams with acquired innovation rather than relying solely on organic development.
The financial arc demonstrates the intensity of this restructuring, moving from steady earnings of $3.12 per share in FY2021 through the deep deficit of 2024 and back to stability. To finance this pivot, management deployed massive capital, completing a $11.75 billion debt offering in early 2024 to fund the acquisition of Karuna Therapeutics for $330.00 per share in cash. By late 2025, focus shifted to liability management, evidenced by a €5.00 billion Euro-denominated note issuance and a cash tender offer to retire up to $7 billion in existing notes. Investors acknowledged the stabilized balance sheet at the close of FY2025, pricing the stock at $53.94 with a price-to-earnings multiple of 15.6x.
Recent Developments (Q3 and Q4 2025)
Following aggressive restructuring, management focused on optimizing capital structure throughout Q4 2025. The company finalized a Euro-denominated debt issuance with favorable interest rates ranging from 2.973% to 4.581% and maturities extending through 2055, securing long-term liquidity to backstop R&D ambitions. This financial engineering supports a strategic emphasis on acquisitions and licensing to offset looming patent expiries, a core theme in recent updates regarding portfolio resilience.
Investor sentiment strengthened following the fiscal year close, with shares advancing to $59.93 by February 10, 2026, pushing the price-to-earnings multiple to 17.3x. The bull case rests on successful pipeline execution funded by this stabilized balance sheet, while the bear case cites persistent pricing constraints and competitive risks that could dampen future margin expansion.
What to watch: commercial uptake of new product launches; impact of regulatory pricing pressures on gross margins.
Rev
$48.19B
FY2025
NI
$7.05B
FY2025
EPS$BMY
$3.47
FY2025
OCF
$14.16B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Feb 5, 2026)
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on February 5, 2026, to announce its financial results for the fourth quarter and full year of 2025. The filing includes a press release (Exhibit 99.1) detailing these results and a presentation (Exhibit 99.2) covering financial and operating initiatives. Investors should refer to these documents, available on the company's website, for a comprehensive understanding of BMY's recent performance and strategic direction. Both the press release and presentation reference non-GAAP financial information. The company emphasizes that reconciliations between non-GAAP and GAAP measures, along with explanations for the use of non-GAAP figures, are provided within the press release. Investors are advised to review these reconciliations carefully when evaluating the company's financial health and operational efficiency.
BRISTOL MYERS SQUIBB CO 8-K Report, Regulation FD Disclosure (Jan 12, 2026)
Bristol-Myers Squibb Company (BMY) has filed a Form 8-K on January 12, 2026, to disclose an investor presentation made available on their website on January 11, 2026. This presentation, attached as Exhibit 99.1, is intended to provide updates and insights to investors regarding the company's strategic direction, performance, and future outlook. While the filing itself does not contain new financial results or material events beyond the presentation, it serves as a crucial communication channel for investors seeking the latest information directly from the company. Investors are encouraged to review the presentation for details on BMY's ongoing initiatives, pipeline updates, and market positioning, as this is the primary vehicle through which the company is sharing this information in connection with this filing.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Nov 18, 2025)
Bristol Myers Squibb Company (BMY) has filed an 8-K report detailing the results of its previously announced cash tender offers for its outstanding notes. The company announced early participation results on November 17, 2025, and on November 18, 2025, it released the accepted amounts and pricing terms of these offers. These tender offers are part of a strategy to manage its debt obligations, with full details provided in the Offer to Purchase document dated November 3, 2025. Investors should note that this filing primarily concerns debt management and does not represent an offer to buy or sell equity securities. The early participation results and final pricing indicate the company's progress in its debt restructuring efforts, which could impact its financial leverage and interest expense going forward. The full financial implications will be clearer as the settlement process concludes and is reflected in future financial statements.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Nov 10, 2025)
Bristol Myers Squibb Company (BMY) has announced the successful completion of a significant public offering of €5.00 billion in aggregate principal amount of senior unsecured notes, issued by its wholly-owned Irish subsidiary, BMS Ireland Capital Funding Designated Activity Company. The offering comprises notes with maturities ranging from 2030 to 2055 and interest rates from 2.973% to 4.581%. These notes are fully and unconditionally guaranteed by Bristol Myers Squibb Company. The primary purpose of this capital raise is to fund the company's tender offer to repurchase various series of its outstanding notes, as well as to cover associated fees and expenses. Any remaining proceeds will be allocated for general corporate purposes. This debt issuance signifies a strategic move by Bristol Myers Squibb to manage its existing debt obligations and optimize its capital structure.
BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Nov 3, 2025)
Bristol-Myers Squibb Company (BMY) has announced the initiation of cash tender offers to repurchase up to $7 billion of its outstanding notes. This move suggests the company is actively managing its debt obligations, potentially aiming to optimize its capital structure or take advantage of favorable market conditions for debt buybacks. Investors should note that this tender offer is a significant financial maneuver that could impact the company's liquidity and leverage ratios. The details of the offer, including pricing and specific notes targeted, are outlined in the company's Offer to Purchase dated November 3, 2025. The aggregate purchase price is capped at $7 billion, with further limitations specified for different note pools.
View all 8-K filings →